Hernández-Perera JC, Piñeiro-Pérez D, Martínez-Muñiz JO, Correa-Padilla JM, de Armas-Fernández MC, Jordán-González JA, Dávila-Gómez CA, Domínguez-Romero A, Contino-López R

Idioma: Ingles.
Referencias bibliográficas: 16
Paginas: 57-60
Archivo PDF: 232.05 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Himmel M, Frey S. SARS-CoV-2: internationalinvestigation under the WHO or BWC. FrontPublic Health. 2022 Feb 3;9:636679. https://doi.org/10.3389/fpubh.2021.636679

2. Pillai A, Lawson B. Coronavirus disease 2019and cardiovascular diseases: collateral damage?Curr Opin Anesthesiol. 2022 Feb 1;35(1):5–11.https://doi.org/10.1097/aco.0000000000001076

3. Oleynick C. Symptoms of pleurisy as the initialpresentation of COVID-19. Am J Case Rep. 2020Jul 24;21:e925775. https://doi.org/10.12659/ajcr.925775

4. Ucan B, Kaynak Sahap S, Cinar HG, Tasci YildizY, Uner C, Polat M, et al. Multisystem infl ammatorysyndrome in children associated with SARSCoV-2: extracardiac radiological fi ndings. Br JRadiol. 2022 Jan 1;95(1129):20210570. https://doi.org/10.1259/bjr.20210570

5. Boix V, Merino E. Síndrome post-COVID. Eldesafío continúa [Post-COVID syndrome. Thenever ending challenge]. Med Clin (Barc). 2022 Feb25;158(4):178–80. Epub 2021 Dec 2. https://doi.org/10.1016/j.medcli.2021.10.002. Spanish, English.

6. Messin L, Puyraveau M, Benabdallah Y, LepillerQ, Gendrin V, Zayet S, et al. COVEVOL:Natural evolution at 6 months of COVID-19.Viruses. 2021 Oct 25;13(11):2151. https://doi.org/10.3390/v13112151

7. Harris E, Shanghavi S, Viner T. Polyserositissecondary to COVID-19: the diagnostic dilemma.BMJ Case Rep. 2021 Sep 27;14(9):e243880.https://doi.org/10.1136/bcr-2021-243880

8. Klimek-Piotrowska W, Mizia E, Kużdżał J, LazarA, Lis M, Pankowski J. Ectopic thymic tissue inthe mediastinum: limitations for the operativetreatment of myasthenia gravis†. Eur J CardiothoracSurg. 2012 Jul 1;42(1):61–5. https://doi.org/10.1093/ejcts/ezr268

9. Losada I, González-Moreno J, Roda N, VentayolL, Borjas Y, Domínguez FJ, et al. Polyserositis:a diagnostic challenge. Intern Med J.2018 Aug;48(8):982–7. https://doi.org/10.1111/imj.13966

10. Refaat MM, Katz WE. Neoplastic pericardialeff usion. Clin Cardiol. 2011 Oct;34(10):593–8.https://doi.org/10.1002/clc.20936

11. Wu Y-B, Xu L-L, Wang X-J, Wang Z, Zhang J,Tong Z-H, et al. Diagnostic value of medical thoracoscopyin malignant pleural eff usion. BMCPulm Med. 2017 Aug 4;17(1):109. https://doi.org/10.1186/s12890-017-0451-1

12. Mizia E, Klimek-Piotrowska W, Kużdżał J, KonopkaT, Lis M, Pankowski J, et al. Residua of thymusin the mediastinum - clinical aspects - cadavericstudy. Folia Med Cracov [Internet]. 2017 [cited2022 Feb 7];LVII(1):23–8. Available at: http://www.fmc.cm-uj.krakow.pl/pdf/57_1_23.pdf

13. Piccioni A, Brigida M, Loria V, Zanza C,Longhitano Y, Zaccaria R, et al. Role of troponinin COVID-19 pandemic: a review of literature.Eur Rev Med Pharmacol Sci. 2020Oct;24(19):10293–300. https://doi.org/10.26355/eurrev_202010_23254

14. Rodríguez Y, Novelli L, Rojas M, De Santis M,Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions atthe crossroad of COVID-19. J Autoimmun.2020 Nov;114:102506. https://doi.org/10.1016/j.jaut.2020.102506

15. Furqan MM, Verma BR, Cremer PC, Imazio M,Klein AL. Pericardial diseases in COVID19: acontemporary review. Curr Cardiol Rep. 2021Jun 3;23(7):90. https://doi.org/10.1007/s11886-021-01519-x

16. Deftereos SG, Giannopoulos G, Vrachatis DA,Siasos GD, Giotaki SG, Gargalianos P, et al.Eff ect of colchicine vs standard care on cardiacand infl ammatory biomarkers and clinicaloutcomes in patients hospitalized with CoronavirusDisease 2019: the GRECCO-19 randomizedclinical trial. JAMA Netw Open. 2020 Jun1;3(6):e2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136